Compare MasTec Inc (MTZ) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Novartis AG — how do they compare? MasTec Inc trades at $219.65 (market cap $17.94B), while Novartis AG trades at $142.74 (market cap $274.00B). The key difference: Novartis AG is far larger — about 15.3× MasTec Inc's market cap, and Novartis AG pays a 3.31% dividend while MasTec Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasTec Inc for 23 Days and Novartis AG for 82 Days on average.
| MTZ | NVS | |
|---|---|---|
Market Cap | $17.94B | $274.00B |
Volume | 1,292,386 | 1,852,137 |
Sector | Industrials | Health |
52-Week High | $437.51 | $168.62 |
52-Week Low | $190.08 | $121.80 |
Typical Hold Time | 23 Days | 82 Days |
Enterprise Value | $20.86B | $315.32B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $223.37, down 2.16% today, with technical indicators showing a neutral bias amid mixed moving average signals. The company reported strong Q1 2026 earnings beat but missed Q2 expectations, while maintaining robust revenue growth projections for 2026. Analyst sentiment remains overwhelmingly positive with 88.9% buy ratings and a $408.58 consensus price target representing significant upside potential from current levels.
MTZ's infrastructure expertise positions it well for AI-driven data center and utility investment cycles, though premium valuation metrics and recent cash flow volatility present near-term risks. The stock's investment case hinges on execution of record backlog and margin expansion amid competitive infrastructure markets.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
